Parkinson’s disease therapeutic market

Nov 18, 2024

Parkinson’s disease is the second most common neurodegenerative disorder after Alzheimer’s disease. It affects about 10 million people worldwide. The average age of onset for Parkinson’s disease is around 60; however, approximately 10-15% of patients experience early-onset PD before the age of 50. In 2023, there...

Dec 30, 2022

Parkinson’s disease (PD) is a degenerative neurological condition primarily affecting middle-aged and older adults and is characterized by tremors, muscular rigidity, and slow, clumsy movement. It is connected to the brain’s basal ganglia atrophy and a lack of the neurotransmitter dopamine. Levodopa is considered a...

Nov 15, 2022

Genentech’s gantenerumab Fails in Phase III Trial for Alzheimer’s Disease In yet another setback for an amyloid-targeting drug, Roche's Genentech division has reported disappointing top-line results from its highly anticipated phase III trial of gantenerumab in early Alzheimer's disease. The failure is entirely ...

Dec 31, 2021

Parkinson's disease is a neurodegenerative disorder that affects predominately dopamine-producing (“dopaminergic”) neurons in a specific area of the brain called substantia nigra. Parkinson's disease has four main symptoms such as tremor (trembling) in hands, arms, legs, jaw, or head, stiffness of the limbs and tru...

Jan 26, 2021

Hot on the heels, Aurinia launches its drug in the Lupus market after GSK Aurinia Pharmaceuticals has recently got the USFDA approval for its Lupkynis (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active Lupus nephritis (LN). Lupkynis is the first o...

Jan 11, 2021

Neurological disorders are the leading source of disability globally, and Parkinson's is the fastest-growing neurological condition. It could be due to several factors ranging from an increase in geriatric population, longevity, improved diagnostics methodologies, a better understanding of the disease to the specif...

Jul 09, 2019

NICE recommends Pfizer’s Vizimpro for treating NSCLC Not long ago, Pfizer’s Vizimpro (dacomitinib) a tyrosine kinase inhibitor (TKI), was approved as a first-line monotherapy treatment for adult patients living with locally advanced or metastatic non-small lung cancer (NSCLC). As evaluated by the American Cancer...

Apr 29, 2019

Parkinson's Awareness Month April marks Parkinson's Awareness Month, is an occasion to spread awareness about Parkinson’s. Not the early signs as they are more than just any tremor! Parkinson’s changes everything. Over 10 Million people are living with Parkinson’s worldwide yet the condition remains a mystery. ...

Apr 22, 2019

Parkinson's Disease (PD) is a chronic and progressive movement disorder which primarily affects dopamine-producing (“dopaminergic”) neurons in a specific area of the brain called substantia nigra.  These neurons are usually responsible for the control and coordination process, which during the neuron malfuncti...